Your assumptions are "interesting" as well as your conclusions. There's way too many to cover each one, I'll just take the 1 section for fun.
>"... the current CEO who we all know volunteered for her current position in the company....
She has NEVER been a volunteer. She's been paid... OVER PAID I would say!
"...hedge funds have been aggressively shorting the stock to its current price "
Absolutely no evidence of this. Indeed, the short figures have been at or around 0 for a long time. Latest and biggest is recently at 209M shares, but that's with knowing BILLIONS of rule 144 shares will have to be issued to cover the 756,000 that was due over a week ago. That's a fact reported in their 10-Q.
"...force a buyout of the CEO's stake in the company and all 35 patents, "
ROFL. She owns most of them PERSONALLY. Nobody could force anything there.
"..that includes the LILA technology under development by Bioscan (which Bioscan is paying royalties for). "
LILA paid one payment, and no more. Nothing is happening there, they've removed all references from their web site years ago.
"The filing for the A/S increase described how it was for ongoing capital and what not, but out of NOWHERE and I mean NOWHERE there was this sentence: "It is to be used as an anti-takeover device."
You should read their SEC filings more closely...
"We may issue preferred stock at any time to prevent a takeover or acquisition, any of which issuance could dilute the price of our common stock.
Our articles of incorporation authorize the issuance of preferred stock with designations, rights, and preferences that may be determined from time to time by the board of directors. Our board of directors is empowered, without stockholder approval, to designate and issue additional series of preferred stock with dividend, liquidation, conversion, voting and other rights, including the right to issue convertible securities with no limitations on conversion, which could adversely affect the voting power or other rights of the holders of our common stock. This could substantially dilute the common shareholders’ interest and depress the price of our common stock. In addition, the preferred stock could be utilized as a method of discouraging, delaying or preventing a change-in-control. The substantial number of issued and outstanding convertible preferred stock and the convertible debentures, and their terms of conversion may discourage or prevent an acquisition of our company."
>"Not to mention the CEO took away voting rights of shareholders obviously because those hedgies would have voted against her. "
There are no 'hedgies' just TOXIC LENDERS. And yea, they may have voted her out to put someone in there that knew what they're doing!
>"The delay in news this week is also because we believe the FDA application is being submitted which takes a couple weeks. "
LMAO!! They have not even APPLIED to do a new Clinical Study, which needs approval before they can start a study! NONE of their previous scans will ba admissable as they're going under DOT, right?? And a study would take over a year and cost millions. Neither thee time nor money do they have. But I appreciate your humor.
AI
Market Data 
Markets 
